Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer

NCT00500760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma

Interventions

DRUG: Cisplatin
RADIATION: Standard Fractionation Radiotherapy
DRUG: Panitumumab

Sponsor

Amgen